Guidelines of care for the management of psoriasis and psoriatic arthritis : Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions - 28/07/11
Abstract |
Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In the first 5 parts of the AmericanAcademy of Dermatology Psoriasis Guidelines of Care, we have presented evidence supporting the use of topical treatments, phototherapy, traditional systemic agents, and biological therapies for patients with psoriasis and psoriatic arthritis. In this sixth and final section of the Psoriasis Guidelines of Care, we will present cases to illustrate how to practically use these guidelines in specific clinical scenarios. We will describe the approach to treating patients with psoriasis across the entire spectrum of this fascinating disease from mild to moderate to severe, with and without psoriatic arthritis, based on the 5 prior published guidelines. Although specific therapeutic recommendations are given for each of the cases presented, it is important that treatment be tailored to meet individual patients’ needs. In addition, we will update the prior 5 guidelines and address gaps in research and care that currently exist, while making suggestions for further studies that could be performed to help address these limitations in our knowledge base.
Le texte complet de cet article est disponible en PDF.Key words : adalimumab, alefacept, biologics, case studies, clinical guidelines for psoriasis, combination therapy, comorbidities, dermatology, etanercept, gaps in knowledge, gaps in research, golimumab, guidelines, inflammation, infliximab, methotrexate, narrowband, phototherapy, psoralen plus ultraviolet A, psoriasis, psoriatic arthritis, skin disease, systemic therapy, therapeutic recommendations, topical treatments, traditional systemic therapy, tumor necrosis factor-alfa, ustekinumab
Abbreviations used : AAD, BB, BSA, FDA, IL, LFT, MTX, NB, NSAIDs, PASI, PASI-75, PsA, PUVA, SCC, TNF, UV
Plan
Funding sources: None. |
|
The authors’ conflict of interest/disclosure statements appear at the end of the article. |
Vol 65 - N° 1
P. 137-174 - juillet 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?